Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GUTS NASDAQ:KRMD NASDAQ:SURG NASDAQ:TLSI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGUTSFractyl Health$1.81-1.6%$1.84$0.87▼$3.72$90.12M1.66229,265 shs112,220 shsKRMDKORU Medical Systems$3.48+0.6%$3.31$1.86▼$5.05$159.65M0.47122,220 shs145,042 shsSURGSurgePays$2.70-1.8%$2.95$1.05▼$3.47$56.13M0.4668,052 shs124,983 shsTLSITriSalus Life Sciences$4.18-1.2%$5.07$3.50▼$6.04$160.06M0.539,551 shs60,247 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGUTSFractyl Health-1.63%-5.73%+10.37%+14.56%-43.26%KRMDKORU Medical Systems+0.58%+0.58%-4.40%+22.11%+50.00%SURGSurgePays-1.82%-8.16%-14.56%-0.74%-8.47%TLSITriSalus Life Sciences-1.18%-8.33%-14.69%-18.20%-26.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGUTSFractyl Health1.6187 of 5 stars3.53.00.00.00.00.00.0KRMDKORU Medical Systems2.5365 of 5 stars3.53.00.00.01.02.50.6SURGSurgePays3.2424 of 5 stars3.55.00.00.02.51.70.6TLSITriSalus Life Sciences2.2113 of 5 stars3.62.00.00.00.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGUTSFractyl Health 3.00Buy$11.00507.73% UpsideKRMDKORU Medical Systems 3.00Buy$4.6332.90% UpsideSURGSurgePays 3.00Buy$9.00233.33% UpsideTLSITriSalus Life Sciences 3.25Buy$10.75157.18% UpsideCurrent Analyst Ratings BreakdownLatest SURG, KRMD, TLSI, and GUTS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025SURGSurgePaysAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.75 ➝ $9.005/8/2025KRMDKORU Medical SystemsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$4.50 ➝ $3.50(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGUTSFractyl Health$90K985.04N/AN/A$0.59 per share3.07KRMDKORU Medical Systems$33.65M4.77N/AN/A$0.37 per share9.41SURGSurgePays$40.03M1.38N/AN/A$0.76 per share3.55TLSITriSalus Life Sciences$32.14M4.92N/AN/A($0.83) per share-5.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGUTSFractyl Health-$68.69M-$1.85N/AN/AN/A-73,864.52%-228.66%-76.74%8/13/2025 (Estimated)KRMDKORU Medical Systems-$6.07M-$0.11N/AN/AN/A-15.09%-30.43%-19.41%8/6/2025 (Estimated)SURGSurgePays-$45.73M-$2.79N/AN/AN/A-136.37%-206.01%-153.67%8/12/2025 (Estimated)TLSITriSalus Life Sciences-$30.05M-$1.12N/AN/AN/A-84.67%N/A-111.63%8/13/2025 (Estimated)Latest SURG, KRMD, TLSI, and GUTS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025GUTSFractyl Health-$0.37N/AN/AN/AN/AN/A8/13/2025Q2 2025TLSITriSalus Life Sciences-$0.22N/AN/AN/A$10.69 millionN/A8/12/2025Q2 2025SURGSurgePays-$0.31N/AN/AN/A$16.14 millionN/A8/6/2025Q2 2025KRMDKORU Medical Systems-$0.03N/AN/AN/A$9.46 millionN/A5/15/2025Q1 2025TLSITriSalus Life Sciences-$0.20-$0.33-$0.13-$0.39$9.04 million$9.17 million5/13/2025Q1 2025GUTSFractyl Health-$0.49-$0.49N/A-$0.49N/AN/A5/13/2025Q1 2025SURGSurgePays-$0.40-$0.38+$0.02-$0.38$9.80 million$10.58 million5/7/2025Q1 2025KRMDKORU Medical Systems-$0.02-$0.03-$0.01-$0.03$8.86 million$9.64 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGUTSFractyl HealthN/AN/AN/AN/AN/AKRMDKORU Medical SystemsN/AN/AN/AN/AN/ASURGSurgePaysN/AN/AN/AN/AN/ATLSITriSalus Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGUTSFractyl Health4.612.502.50KRMDKORU Medical Systems0.012.442.02SURGSurgePays0.241.721.41TLSITriSalus Life SciencesN/A2.141.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGUTSFractyl HealthN/AKRMDKORU Medical Systems58.60%SURGSurgePays6.94%TLSITriSalus Life Sciences2.58%Insider OwnershipCompanyInsider OwnershipGUTSFractyl HealthN/AKRMDKORU Medical Systems20.60%SURGSurgePays30.50%TLSITriSalus Life Sciences27.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGUTSFractyl Health10248.98 millionN/AN/AKRMDKORU Medical Systems8046.14 million36.64 millionOptionableSURGSurgePays4020.41 million14.19 millionOptionableTLSITriSalus Life Sciences10637.84 million27.43 millionNot OptionableSURG, KRMD, TLSI, and GUTS HeadlinesRecent News About These CompaniesTriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth ConferenceJuly 30 at 4:05 PM | businesswire.comTriSalus Life Sciences (NASDAQ:TLSI) Stock Price Down 4.6% - Should You Sell?July 30 at 4:06 AM | marketbeat.comTriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference CallJuly 29, 2025 | businesswire.comTriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred StockJuly 24, 2025 | businesswire.comTriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System - Business WireJune 25, 2025 | businesswire.comTriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital StructureJune 23, 2025 | businesswire.comTriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. PatienceMay 30, 2025 | businesswire.comJodi Devlin Sells 4,764 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) StockMay 22, 2025 | insidertrades.comTriSalus outlines at least 50% revenue growth for 2025 as new Medicare code expands addressable marketMay 15, 2025 | msn.comTriSalus Life Sciences, Inc. (TLSI) Q1 2025 Earnings Conference Call TranscriptMay 15, 2025 | seekingalpha.comTriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue EstimatesMay 15, 2025 | zacks.comTriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 GuidanceMay 15, 2025 | businesswire.comTriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference CallMay 12, 2025 | businesswire.comTriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial ResultsApril 30, 2025 | finance.yahoo.comTriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock?April 9, 2025 | zacks.comTriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock?April 9, 2025 | zacks.comTriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still RisksMarch 30, 2025 | seekingalpha.comTrisalus outlines 50% revenue growth target for 2025 driven by TriNav expansion and new market penetrationMarch 27, 2025 | msn.comTriSalus Life Sciences’ Q4 Loss Exceeds Projections, Revenue Tops Estimates – Retail Stays PessimisticMarch 27, 2025 | msn.comTriSalus Life Sciences, Inc. (TLSI) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comTriSalus Life Sciences, Inc. (TLSI) Reports Q4 Loss, Tops Revenue EstimatesMarch 27, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesPalantir’s Revenue Surge to $1B: Growth vs. ValuationBy Chris Markoch | July 9, 2025View Palantir’s Revenue Surge to $1B: Growth vs. ValuationThese 3 Rare Earth Stocks Are Surging Alongside MP MaterialsBy Leo Miller | July 19, 2025View These 3 Rare Earth Stocks Are Surging Alongside MP MaterialsThese 3 Undervalued Stocks Could Surge as Value Rotation NearsBy Gabriel Osorio-Mazilli | July 14, 2025View These 3 Undervalued Stocks Could Surge as Value Rotation NearsRocket Lab: A Parabolic Run Meets a Healthy PullbackBy Ryan Hasson | July 23, 2025View Rocket Lab: A Parabolic Run Meets a Healthy PullbackThe Meteoric Rise of Rocket Lab: A Space Stock to WatchBy Ryan Hasson | July 11, 2025View The Meteoric Rise of Rocket Lab: A Space Stock to WatchSURG, KRMD, TLSI, and GUTS Company DescriptionsFractyl Health NASDAQ:GUTS$1.81 -0.03 (-1.63%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.74 -0.07 (-3.87%) As of 08/1/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.KORU Medical Systems NASDAQ:KRMD$3.48 +0.02 (+0.58%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.48 0.00 (-0.14%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.SurgePays NASDAQ:SURG$2.70 -0.05 (-1.82%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.70 +0.00 (+0.19%) As of 08/1/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SurgePays, Inc., together with its subsidiaries, operates as a financial technology and telecom company in the United States. It operates through three segments: Mobile Virtual Network Operators, Comprehensive Platform Services, and Lead Generation. The company offers subsidized and non-subsidized mobile virtual network operators for internet connectivity through mobile broadband services to consumers; ACH banking relationships and fintech transactions platform to convenience stores; wireless top-up transactions and wireless product aggregation; and lead generation and case management solutions primarily to law firms in the mass tort industry, as well as call center activities. SurgePays, Inc. is headquartered in Bartlett, Tennessee.TriSalus Life Sciences NASDAQ:TLSI$4.18 -0.05 (-1.18%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.18 +0.00 (+0.12%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
